U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07360080) titled 'Long-Term Outcomes of Teplizumab in Routine Clinical Care' on Jan. 14.
Brief Summary: This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D. The study will monitor participants receiving teplizumab as part of routine clinical care across multiple sites. Additionally, patient-reported outcomes (PROs) will be evaluated to further assess the treatment's impact on participant's quality of life including emotional and psychosocial aspects associated with T1D. This approach will provide a more ...